Seneca Therapeutics Announces Publication of TEM8 Review Article “TEM8 in Oncogenesis” in Cells Journal

Authors include Dr. Paul Hallenbeck, President and Chief Scientific Officer at Seneca Therapeutics

PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc., announced today the publication of “TEM8 in Oncogenesis” in Cells. The authors are Dr. Samuel Kareff and Dr. Aman Chauhan from Sylvester Cancer at University of Miami, Dr. Virginia Corbett from Mt. Sinai Tisch Cancer Center and Dr. Paul Hallenbeck from Seneca Therapeutics.

“In the article, we underline TEM8’s prognostic and predictive abilities in various solid tumors by (1) highlighting its association with more aggressive disease biology and poor clinical outcomes and (2) assessing its associated clinical trial landscape,” said Dr. Aman Chauhan. “Finally, we offer future directions for clinical studies involving TEM8, including incorporating preclinical agents into clinical trials and combining previously tested oncologic therapies with currently available treatments, such as immunotherapy.”

“The evidence of TEM8’s abilities and role in a broad range of solid tumors continues to grow,” said Dr. Paul Hallenbeck. “This review article provides an excellent update on both TEM8, ANTXR1 - the gene that encodes TEM8 - and SVV-001 which targets TEM8. This update provides a foundation for upcoming publications and clinical trials for SVV-001 and TEM8.”

Seneca Therapeutics is developing SVV-001, a number of SVV-001 armed constructs and a multiple IV option for SVV-001 sensitive solid tumors. SVV-001 sensitivity is defined as high ANTXR1 (TEM8) expression and a microtumor environment which permits replication of SVV-001 in the tumor. Seneca has developed an SVV-001 Companion Diagnostic and received FDA clearance to use it in clinical trials to identify patients that would benefit from SVV-001.

About Seneca Therapeutics

Seneca Therapeutics was founded to capitalize on the profound tumor specificity of SVV and further the development of SVV-001 in several upcoming clinical trials and the creation and testing of armed derivatives selectively expressing gene product(s) that are inserted into the genome of SVV-001 that create additional anti-tumor effects.

Forward-Looking Statements

This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason.